Arrowhead Subsidiary Calando Pharmaceuticals Enters into License Agreement with Cerulean Pharma Inc. - Calando To License Cyclosert TM Platform and Associated IT-101 Drug Candidate for Upfront Payment ...

Calando Pharmaceuticals Inc., a majority-owned subsidiary of Arrowhead Research Corporation has provided more detail on its product and business goals for 2007. "We have made considerable progress ...

PASADENA, Calif. - November 4, 2009 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its majority owned subsidiary, Calando Pharmaceuticals, Inc ...

Calando recently proved systemic siRNA delivery and RNAi-mediated mRNA knockdown. Arrowhead Research has increased its ownership of majority-owned subsidiary Calando Pharmaceuticals through the ...

Alnylam has the right to opt-in on development and commercialization. Alnylam Pharmaceuticals granted Calando Pharmaceuticals an InterfeRx™ license to discover, develop, and commercialize a synthetic ...

WHEN EXECUTIVES from Calando Pharmaceuticals met with the management team of Agilent Technologies' nucleic acid solutions division, the chemistry was obvious, says John Petrovich, Calando's chief ...

Identify research insights to guide research strategy and grow your impact with our Nature Strategy reports. Actionable insights into research performance. Detailed analysis of strengths and ...